Periprocedural Outcomes Associated With Use of a Left Atrial Appendage Occlusion Device in China

• Published in: JAMA network open 2022-05, Vol.5 (5), p.e2214594-e2214594
• Main Authors: Su, Fangju, Gao, Chao, Liu, Jianzheng, Ning, Zhongping, He, Beng, Liu, Yi, Xu, Yawei, Yang, Bing, Li, Yuechun, Zhang, Junfeng, Zhao, Xianxian, Zhang, Yushun, Hu, Hao, Du, Xianfeng, Xie, Ruiqin, Zhou, Ling, Zeng, Jie, Ruan, Zhongbao, Liu, Haitao, Guo, Jun, Wang, Rutao, Garg, Scot, Soliman, Osama, Holmes, Jr, David R, Serruys, Patrick W, Tao, Ling
• Format: Article
• Language: English
• Subjects: Ablation; Aged; Atrial Appendage - surgery; Atrial Fibrillation - complications; Atrial Fibrillation - surgery; Cardiac arrhythmia; Cardiology; China - epidemiology; Cohort Studies; Embolism - complications; Embolisms; Female; Hemorrhage; Humans; Male; Online Only; Original Investigation; Retrospective Studies; Stroke; Stroke - epidemiology; Stroke - etiology; Stroke - prevention & control; Success; Treatment Outcome
• ISSN: 2574-3805; 2574-3805
• DOI: 10.1001/jamanetworkopen.2022.14594

Left atrial appendage occlusion (LAAO) has emerged as an alternative to anticoagulation for patients with atrial fibrillation. However, the performance of LAAO among East Asian patients is unknown. To document the procedural success rate and configurations, major adverse event rates, and antithrombotic medication regimens during and after LAAO procedures among patients in China. In this cohort study, consecutive patients from 39 Chinese centers undergoing LAAO were prospectively enrolled between April 1, 2019, and October 31, 2020. Periprocedural and intraprocedural techniques and postprocedural medications were left to the surgeon's discretion. Data were analyzed from July 1 to November 1, 2021. LAAO for patients with atrial fibrillation. The main outcomes were procedural success and complication rates periprocedure and major adverse event rates of death, stroke, systemic embolism, and bleeding events at 30 days postprocedure; the composite end point of death, stroke, and systemic embolism was also analyzed. Unadjusted and multivariable-adjusted logistic regression analyses were performed to assess the associations of periprocedural techniques (types of anesthesia, intraprocedural imaging modalities, and combined ablation procedure) with 30-day adverse events. Among 3096 enrolled participants, 1782 participants (57.6%) were men, and the mean (SD) age was 69 (9) years. Participants had a high risk of stroke (mean [SD] cardiovascular risk score, 4.0 [1.8]) and a moderate-to-high risk of bleeding (mean [SD] bleeding risk score, 2.4 [1.2]). A total of 1287 procedures (41.6%) were performed under local anesthesia, while 493 procedures (15.9%) used only fluoroscopy guidance. In 1297 procedures (41.9%), LAAO implantation was combined with radiofrequency ablation or cryoablation for atrial fibrillation. Procedural success was achieved in 3032 patients (97.9%). At 30-day follow-up, the rate of the composite end point of death, stroke, or systemic embolism was 0.52% (95% CI, 0.32%-0.84%), and the rate of any life-threatening or major bleeding was 1.23% (95% CI, 0.90%-1.68%). No significant associations were observed between the procedural success or 30-day adverse events and the types of anesthesia (general or local), intraprocedural imaging (transesophageal echocardiography, fluoroscopy, or intracardiac echocardiography), or whether a combined ablation procedure was performed or not. In centers performing at least 40 procedures per year, compared with those perfor